טוען...
Administered Paricalcitol Dose and Survival in Hemodialysis Patients: A Marginal Structural Model Analysis
PURPOSE: Several observational studies have indicated that vitamin D receptor activators (VDRA), including paricalcitol, are associated with greater survival in maintenance hemodialysis (MHD) patients. However, patients with higher serum parathyroid hormone (PTH), a surrogate of higher death risk, a...
שמור ב:
| הוצא לאור ב: | Pharmacoepidemiol Drug Saf |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4304639/ https://ncbi.nlm.nih.gov/pubmed/22996597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.3349 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|